<DOC>
	<DOCNO>NCT02248883</DOCNO>
	<brief_summary>To demonstrate tipranavir ( TPV ) co-administered ritonavir ( RTV ) affect QT interval placebo co-administered ritonavir</brief_summary>
	<brief_title>Electrophysiological Effects Tipranavir Co-administered With Ritonavir QT Interval Healthy Female Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Healthy female male volunteer determine result screen accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , HR ) , 12lead ECG , clinical laboratory test 2 . Age ≥ 18 Age ≤ 55 year 3 . BMI ≥ 18.5 BMI ≤ 29.9 kg/m2 ( Body Mass Index ) 4 . Signed date write informed consent prior admission study accordance GCP local legislation 1 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . Gastrointestinal tract surgery ( except appendectomy ) 3 . Diseases central nervous system ( epilepsy , seizure ) psychiatric disorder neurological disorder 4 . History relevant orthostatic hypotension , faint spell blackout . 5 . Relevant acute , chronic active chronic infection ( e.g . hepatitis , HIV ) . 6 . History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator 7 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial 8 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial 9 . Participation another trial investigational drug within two month prior administration trial 10 . Smoker ( 10 cigarettes/day 3 cigars/day 3 pipes/day ) 11 . Inability refrain smoke trial day 12 . Alcohol abuse ( 60 g/day ) 13 . Drug abuse 14 . Veins unsuited i.v . puncture either arm ( e.g . vein difficult locate , access puncture , vein tendency rupture puncture ) 15 . Blood donation ( 100 mL within four week prior administration trial ) 16 . History bleed disorder acute blood coagulation defect 17 . Hypersensitivity ritonavir , moxifloxacin and/or relate drug class 18 . History Glucose6phosphatedeficiency 19 . Excessive physical activity ( within one week prior trial trial ) 20 . Any laboratory value outside reference range clinical relevance 21 . A history additional risk factor torsade de pointes ( TdP ) ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) 22 . Heart rate screen &gt; 80 bpm &lt; 45 bpm 23 . Any screen ECG value outside reference range clinical relevance include , limited PR interval &gt; 240 m , QRS interval &gt; 120 m , QTcB QTcF &gt; 450 m , QT ( uncorrected ) &gt; 470 m 24 . Inability comply dietary regimen study centre For female subject : 25 . Pregnancy 26 . Positive pregnancy test 27 . No adequate contraception ( adequate contraception e.g . sterilisation , intrauterine pessary ( IUP ) oral contraception contain ethinyl estradiol ) 28 . Oral contraception contain ethinyl estradiol without use additional barrier method 29 . Hormone replacement contain ethinyl estradiol 30 . Inability maintain adequate contraception whole study period 31 . Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>